Because identifying and communicating with patients who are willing to participate in trials can be a significant challenge, Synexus says it is keen to adopt a streamlined process that offers consistency across multiple channels.
Synexus, a site management organization headquartered in Manchester, UK, has appointed business process management company Firstsource Solutions to review and support its strategy for communicating with patients across the United Kingdom. The aim is to create real-time responsiveness and dialogue, leading to an enhanced patient experience throughout the clinical trial process, according to the company.
Because identifying and communicating with patients who are willing to participate in trials can be a significant challenge, Synexus says it is keen to adopt a streamlined process that offers consistency across multiple channels and builds awareness and understanding of the benefits that clinical research can bring for patients, leading to better engagement.
“We selected Firstsource as our partner of choice because of the significant experience they have with major consumer brands that are highly sophisticated when it comes to adopting a multi-channel approach,” noted Sarah Beeby, VP Global Strategic Service Development at Synexus. “We hope to learn from their experiences and apply these to develop a communications strategy that will boost the awareness of clinical trials.”
Targeted messaging of engaging content across various platforms will boost understanding of the benefits of clinical trial participation, and these benefits will carry through the life of the trial by ensuring participants feel well informed and stay motivated to the end of the study, she added.
“In today’s multi-channel world, multiple touch points are becoming a business necessity rather than a ‘nice to have’, and the health sector is no exception,” said Gavin Snell, President, Customer Management, Firstsource Solutions. “Whilst Synexus has offered numerous engagement opportunities to its patients this project will take the business to the next level and really transform the patient experience.”
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.